Sign in

QCLS on Nasdaq

Q/C TECHNOLOGIES, INC.

Q/C TECHNOLOGIES, INC. is an American in vitro and in vivo diagnostic substances company based in New York.1 Its shares trade on Nasdaq under the symbol QCLS.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Celldex Therapeutics, VOLITIONRX LTD or Insight Molecular Diagnostics Inc., or pick any stock.

  • TickerQCLS on Nasdaq1
  • IndustryIn Vitro & In Vivo Diagnostic Substances1
  • HeadquartersNew York, New York1
  • Incorporated inDE2
  • Business address1185 Avenue Of The Americas, Suite 249, New York, Ny 100362
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

LPUs may create economic incentives for adoption among customers operating in energy-intensive computing environments.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

30.4%Gross margin5
-220.2%Operating margin6
-246.6%Net margin6

Where the money goes

Where each dollar of revenue went, fiscal 2019

  • Cost of revenue3¢$46.5K
  • Research and development18¢$276.8K
  • Other costs79¢$1.3M

Out of $1.6M in revenue.756 The company lost money this year.

Financial statements

Fiscal year2019
Revenue$1.6M7
Cost of revenue$46.5K5
Gross profit$478.7K5
Research and development$276.8K5
Operating income-$3.5M6
Income before tax
Income tax
Net income-$3.9M6
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Compare Q/C TECHNOLOGIES, INC. with another company

Corporate structure

Q/C TECHNOLOGIES, INC. sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Q/C TECHNOLOGIES, INC.

  • Q/C TECHNOLOGIES, INC. New York, New York
    • Akers Acquisition Sub, Inc. Subsidiary · New Jersey, United States
    • Bout Time Marketing Corporation Subsidiary · New Jersey, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Q/C TECHNOLOGIES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$10.6K11 Dec 31, 2024$47.4K12 Dec 31, 2023−77.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$987.0K11 Dec 31, 2025$173.2K11 Dec 31, 2024+470.0%
Marketable securities, current$14.8M11 Dec 31, 2025$8.3M11 Dec 31, 2024+77.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$10.5M11 Dec 31, 2025$10.5M11 Dec 31, 20240%
Finite-lived intangibles, net$14.1M11 Dec 31, 2025$170.4K5 Dec 31, 2019+8165.9%

Properties, in its own words

The Company utilities a shared office and service provider as its current corporate headquarters located at 1185 Avenue of the Americas, Suite 249, New York, NY 10036. The Company’s monthly service fee is $136.

The Company leased its former corporate headquarters at an office facility located at 855 North Wolfe Street, Suite 601, Baltimore, Maryland 20215 (the “Maryland Lease”). The Maryland Lease, as amended, had an initial twelve-month term beginning on May 1, 2024, which term automatically renewed thereafter until termination by either party upon 60 days’ notice. The monthly rent of the Maryland Lease is $2,700 and automatically increases 3% on each anniversary date beginning May 1, 2025. On February 26, 2025, the Company provided notice of its intention not to renew the Maryland Lease, effective April 30, 2025.

The rest of Item 2

We believe our current facilities are sufficient and adequate for our current needs.

Item 2 of the 10-K filed Apr 15, 2026.4

Leadership

Who has led Q/C TECHNOLOGIES, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas Albert Nicolette2014
  2. John J. Gormally2015–2018
  3. Howard Yeaton2018–2019

Chair

  1. Raymond Francis Akers Jr.2014–2016
  2. Christopher C. Schreiber2020

President

  1. Thomas Albert Nicolette2014
  2. Christopher C. Schreiber2020
  3. Mitchell Glass2025–now

Chief financial officer

  1. Howard Yeaton2018–2019
  2. Ian Rhodes2021–2026
  3. Charles Todd Fagan2026–now
201520202025
Board members and other officers (21)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive ChairmanJoshua Silverman named Aug 30, 2022 to Sep 5, 202542
  • President, Chief Medical Officer, and DirectorChris Chapman named Aug 30, 2022 to May 31, 202443
  • DirectorBill J. White named Aug 30, 2022 to Sep 5, 202542
  • DirectorBruce Bernstein named Sep 5, 202542

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Akers Acquisition Sub, Inc. New Jersey3
  • Bout Time Marketing Corporation New Jersey3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • TNF Pharmaceuticals, Inc.Jun 27, 2024 to Sep 10, 20252
  • MyMD Pharmaceuticals, Inc.Apr 16, 2021 to Jul 1, 20242
  • Akers Biosciences, Inc.Apr 13, 2017 to Apr 16, 20212
  • Akers Biosciences IncMar 23, 2005 to Apr 11, 20172

Timeline

  1. Sep 18, 20268-K Entered a material agreement; Executive or director change; Regulation FD disclosure44
  2. Sep 11, 20268-K Ended a material agreement; Executive or director change45
  3. Jul 2, 20268-K Ended a material agreement; Other events46
  4. Mar 13, 20268-K Change of auditor47
  5. Jan 23, 20268-K Entered a material agreement; Executive or director change; Other events48
  6. Dec 9, 20258-K Entered a material agreement; Unregistered sale of shares; Other events49
  7. Nov 14, 20258-K Executive or director change; Shareholder vote50
  8. Oct 6, 20258-K Executive or director change51
  9. Oct 3, 20258-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights52
  10. Sep 26, 20258-K Bylaws or fiscal year changed; Regulation FD disclosure53
  11. Sep 10, 20258-K Entered a material agreement; Change to shareholders' rights; Bylaws or fiscal year changed54
  12. Sep 5, 20258-K Financial statements and exhibits55
  13. Oct 16, 2018New chief executive Howard Yeaton becomes CEO13
  14. Dec 29, 2015New chief executive John J. Gormally becomes CEO14
  15. Jan 24, 2014New chief executive Thomas Albert Nicolette becomes CEO15

Calendar

Coming up

  1. Nov 18, 2026Reports results for the quarter ending Sep/202656

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

222 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 80 major events, 54 insider forms, 10 large holders, 4 private raises, 52 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 2, 20264/A EDGAR
  3. Sep 22, 20263 EDGAR
  4. Sep 18, 20268-K EDGAR
  5. Sep 11, 20268-K EDGAR
  6. Aug 17, 20263 EDGAR
  7. Aug 12, 202610-Q EDGAR
  8. Jul 2, 20268-K EDGAR
  9. May 15, 202610-Q EDGAR
  10. May 14, 20264 EDGAR
  11. Apr 29, 202610-K/A EDGAR
  12. Apr 15, 20264 EDGAR
  13. Apr 15, 20264 EDGAR
  14. Apr 15, 20264 EDGAR
  15. Apr 15, 20264 EDGAR
  16. Apr 15, 20264 EDGAR
  17. Apr 15, 20264 EDGAR
  18. Apr 15, 202610-K EDGAR
  19. Mar 31, 2026NT 10-K EDGAR
  20. Mar 13, 20268-K EDGAR

The 222 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 30, 2026Voss Chelsea SierraDirectorBuy1,753$3.15$5.5KForm 4
Aug 24, 2023Rivard PaulChief Legal OfficerBuy150,000$1.11$166.5KForm 4
Aug 17, 2023Rivard PaulChief Legal OfficerBuy25,000$1.12$28.0KForm 4
Dec 8, 2022Rivard PaulChief Legal OfficerBuy10,000$1.53$15.3KForm 4
Nov 26, 2021Silverman JoshuaExecutive ChairmanBuy5,000$7.55$37.8KForm 4
Nov 24, 2021Silverman JoshuaExecutive ChairmanBuy10,000$6.56$65.6KForm 4
Nov 23, 2021Rivard PaulChief Legal OfficerBuy15,000$6.03$90.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$49.0M 2024–2025
Money received by yearMoney received by year, 2024–2025: $49.0M in all. Private raises (Form D) $49.0M.$0$20M$40M$60M2024 · Private raises (Form D): $42.0M20242025 · Private raises (Form D): $7.0M2025
Figures by year
YearPrivate raises (Form D)Total
2025$7.0M$7.0M
2024$42.0M$42.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Sep 2, 2025Raised $7 million in a private offering of equity42 Form D: 12 investors so far Form D
  2. May 20, 2024Raised $26.9 million in a private offering of equity43 Form D: 4 investors so far Form D
  3. May 20, 2024Raised $15.2 million in a private offering of equity63 Form D: 5 investors so far Form D
  4. Aug 15, 2022Filed a private offering of securities64 Form D: $7.4 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Quinn Opportunity Partners LLC123,024$479.8K0.0%−88,366
Vanguard Capital Management LLC115,031$448.6K0.0%+77,520
Jane Street Group, LLC87,241$340.2K0.0%−38,947
Geode Capital Management, LLC70,682$275.7K0.0%+23,292
UBS Group AG58,894$229.7K0.0%−19,095
Balyasny Asset Management L.P.57,692$225.0K0.0%New
ADAR1 Capital Management, LLC50,000$195.0K0.0%No change
Vanguard Fiduciary Trust Co43,053$167.9K0.0%+27,498
State Street Corp25,305$98.7K0.0%+12,400
Dimensional Fund Advisors LP19,058$74.3K0.0%No change
Northern Trust Corp17,997$70.2K0.0%New
Peak6 LLC12,778$49.8K0.0%New
Tower Research Capital LLC (TRC)1,043$4.1K0.0%−550
Barclays PLC950$3.7K0.0%New
SBI Securities Co., Ltd.100$3900.0%New
Hrt Financial LP50,373$1960.0%+27,969
BlackRock, Inc.19$740.0%No change
Caitong International Asset Management Co., Ltd9$350.0%New
Jones Financial Companies Lllp2$70.0%No change
Wilmington Savings Fund Society, FSB1$40.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Q/C TECHNOLOGIES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARQ/C TECHNOLOGIES, INC.1
  • CIK0001321834
  • Employer ID (EIN)22-29837834
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1185 Avenue Of The Americas, Suite 249, New York, NY 100361
  • Phone856-848-86981
  • Shares outstanding8,189,838 as of Aug 12, 20269
  • Public float$3.6M as of Jun 30, 20254
  • AuditorGrassi & Co., CPAs, P.C., Glastonbury, Connecticut PCAOB ID 606; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMar 23, 20051
  • Filings604 in all: 8-K (157), 4 (96), 10-Q (38), CORRESP (32), 3 (31), UPLOAD (26), SC 13G/A (20), DEF 14A (16)1
    All 43 form types

    S-1/A (14), SC 13G (14), 10-K (13), EFFECT (13), 424B5 (11), 8-K/A (11), D (10), DEFA14A (9), PRE 14A (9), S-3 (9), 425 (8), 424B3 (7), NT 10-Q (7), S-3/A (6), 10-K/A (5), 4/A (4), NT 10-K (4), SC 13D (4), 10-Q/A (3), ARS (3), FWP (3), PRER14A (3), S-1 (3), 424B4 (2), 8-A12B (2), REGDEX (2), 5 (1), CERTNAS (1), DEFR14A (1), DRS (1), S-1MEF (1), S-4 (1), S-4/A (1), S-8 (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Oct 20, 2025
    Latest 8-K (8-K) Sep 18, 2026

Securities registered for trading

ClassSymbolExchange
Shares of Common Stock, par value $0.001 per shareQCLSThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Q/C TECHNOLOGIES, INC. names in Item 1A of its 10-K filed Apr 15, 2026: 42 risks under these headings, as written.4

  • Risks Related to Our Business
  • Risks Related to Our Legacy Pharmaceutical Business
  • Risks Related to Our Intellectual Property
  • Risks Related to Our Preferred Stock
  • Risks Related to our Business
  • We expect that we will need to raise additional funding before we can expect to become profitable from our laser-based computing business or any realization of value from our legacy pharmaceutical product candidates. This additional financing may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.
  • We have recently shifted our business strategy from pharmaceutical development to laser-based computing for blockchain and high-performance computing, and we may not successfully develop, validate or commercialize our new technology.
  • We may require significant additional capital to develop the qc-LPU100, finance pilot deployments and other development efforts, and execute our hardware commercialization plan, and we may be unable to obtain such capital on acceptable terms or at all.
  • Our primary source for developing qc-LPU100 and LPU prototypes is through a licensing partnership, and therefore the Company is dependent upon maintaining and increasing the number of licensing agreements and developing annual recurring revenues through those partnerships, in order to continue to develop its business.
  • The market price of our Common Stock has been and may continue to be subject to significant fluctuations and volatility, and the stockholders of the Company may be unable to resell their shares at a profit and may incur losses.
  • We have a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. If we fail to obtain additional funding to conduct our planned research and development efforts, we could be forced to delay, reduce or eliminate our product development programs or commercial development efforts.
  • Our limited operating history related to our laser-based computing technology may make it difficult to evaluate the success of our business to date and to assess our future viability.
The other 35 risks
  • Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate.
  • Certain stockholders could attempt to influence changes within the Company, which could adversely affect our operations, financial condition and the value of our Common Stock.
  • In order to compete, we must attract, retain and motivate key associates, and the failure to do so could have an adverse effect on our business, financial condition and results of operations.
  • We have a very limited workforce and are highly dependent on a small number of individuals to execute our business strategy, which exposes us to significant operational risk.
  • The quantum computing industry is competitive and we may not be successful in competing in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and customers.
  • Even if we are successful in developing qc-LPU100 and LPU prototypes, competitors in the industry may achieve technological breakthroughs that render our systems obsolete or inferior to other technology.
  • The quantum-class laser computing industry is in its early stages and volatile, and if it does not develop, if it develops slower than we anticipate, if it encounters negative publicity or if quantum computing products and services generally do not achieve commercial adoption, the growth of our business will be harmed.
  • The cryptocurrency and blockchain markets are highly volatile, and a sustained downturn in cryptocurrency prices or demand could materially reduce the market for our laser-based computing products.
  • Unfavorable conditions in our industries or the global economy could limit our ability to grow our business and negatively affect our results of operations.
  • Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security or those of third-party providers.
  • Our legacy pharmaceutical product candidates, Isomyosamine and Supera-CBD, are subject to extensive clinical development, regulatory approval, and commercialization risks that could reduce the value of these assets.
  • Any legacy pharmaceutical product candidate that obtains marketing approval would be subject to extensive post-marketing regulatory requirements, and could be subject to restrictions or withdrawal from the market.
  • The commercial viability of our legacy pharmaceutical product candidates is dependent on market acceptance, pricing, reimbursement, and competition, any of which could reduce the value of these assets.
  • The Company’s legacy pharmaceutical operations are subject to healthcare laws and regulations, including anti-kickback, fraud and abuse, and healthcare reform legislation, which could affect the value of these pharmaceutical assets.
  • Our legacy pharmaceutical operations involve the use of hazardous materials, and we are subject to environmental, health, and safety laws and regulations.
  • Risks Related to Government Regulation
  • Our focus on blockchain and cryptocurrency infrastructure exposes us to regulatory, cybersecurity, and market risks that could materially impact adoption of our technology.
  • We may be subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.
  • We may not be able to adequately protect or enforce our intellectual property rights, which could harm our competitive position.
  • Our business depends on our exclusive global licensing agreement with LightSolver, and loss of access to this technology or disputes regarding intellectual property could materially and adversely affect our operations.
  • Third-party claims of intellectual property infringement may prevent, delay or otherwise interfere with our business operations.
  • Holders of our Series H Preferred Stock and Series G Preferred Stock are entitled to certain payments under the applicable Certificate of Designations that may be paid in cash, in shares of Common Stock or in additional shares of Series G Preferred Stock depending on the circumstances. If we make these payments in cash, it may require the expenditure of a substantial portion of our cash resources. If we make these payments in Common Stock, it may result in substantial dilution to the holders of our Common Stock.
  • Certain outstanding shares of preferred stock and common stock purchase warrants of the Company contain anti-dilution provisions that may result in the reduction of the conversion price of the applicable preferred stock or the exercise price of such warrants in the future. These features may increase the number of shares of Common Stock being issuable upon conversion of such preferred stock or upon the exercise of such warrants.
  • The Series H Certificate of Designations and Series G Certificate of Designations contains restrictive covenants and terms that may make it difficult to procure additional financing and that may affect our financial condition and results of operations.
  • Under the Series H Purchase Agreement and Series G Purchase Agreement, we are subject to certain restrictive covenants that may make it difficult to procure additional financing.
  • General Risk Factors
  • Offers or availability for sale of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline.
  • An active trading market for our Common Stock may not be sustained.
  • We are subject to various internal control reporting requirements under the Sarbanes-Oxley Act. We can provide no assurance that we will at all times in the future be able to report that our internal controls over financial reporting are effective.
  • We incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results.
  • If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
  • We may issue additional equity securities in the future, which may result in dilution to existing investors.
  • We do not anticipate paying cash dividends on our Common Stock and, accordingly, stockholders must rely on stock appreciation for any return on their investment.
  • If securities analysts do not publish research or reports about our business, or if they publish negative evaluations, the price of our Common Stock could decline.
  • Anti-takeover provisions of our certificate of incorporation, our bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove the current members of our board and management.
  • We may be subject to securities litigation in the future.
  • Current market and economic conditions in one or more of our markets could impact our ability to grow our business.

Legal proceedings

From time to time, we are a party to litigation and subject to claims incident to the ordinary course of business. Future litigation may be necessary to defend ourselves and our customers by determining the scope, enforceability, and validity of third-party proprietary rights or to establish our proprietary rights. For a discussion of material legal proceedings affecting us as of December 31, 2025, please read Note 8 to the consolidated financial statements under “Litigation and Settlements,” which information is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64